Why Roche Holding Stock Popped Today
Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears…
FDA pushes back decision on Sanofi’s BTK inhibitor; Roche makes a deal with Starpharma
Plus, news about Sciwind Biosciences, Ipsen, Genfit, Ascletis, AusperBio, Ensoma, Jasper Therapeutics, Verrica, Incyte and Johnson & Johnson:…
Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met…
Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met…
Roche MS drug fenebrutinib cuts relapses 51% in Phase III
Roche (OTCQX: RHHBY) reported that the pivotal Phase III study FENhance 1 met…
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary…
Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial
Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…
Swiss pharmaceuticals company Roche announces $50B investment in US over next 5 years
GENEVA (AP) — Swiss pharmaceuticals powerhouse Roche announced Tuesday it plans to invest $50 billion in the United…
Roche Holding (SWX:ROG) Is Up 9.4% After Positive Phase III Results in MS and Lupus—Has the Bull Case Changed?
Roche has reported highly positive Phase III results for its investigational drugs fenebrutinib in multiple sclerosis and Gazyva/Gazyvaro…
Data builds on Roche’s dominance in primary progressive MS
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in…
RHHBY’s 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER
Swiss pharma giant Roche Holding AG’s RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion,…